Roxana Mehran, MD

Country USA
Specialty Interventional Cardiologist
  1. Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More
  2. Year-In-Review: Interventional Pharmacology
  3. Optimal DAPT Duration for PCI Patients at High Beeding Risk
  4. Potent P2Y12 Inhibitors for East-Asian Patients: Insights from the TWIGHLIGHT in Western vs. Asian Population
  5. Interventional Pharmacology Year-In-Review
  6. Aspirin Plus NOAC Will Be the Standard of Care.
  7. HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-based DES with a Luminal CD34+ Antibody Coating Versus a Durable Polymer-based DES in Patients with Coronary Artery Disease
  8. Optimal Balancing Ischemic and Bleeding Risks in Contemporary PCI Practice: TWILIGHT, GLOBAL-LEADER and More...
  9. Optimal Initiation and Duration of DAPT in ACS Patient; Reviewing the Evidence of Ticagrelor
  10. Pretreatment with P2Y12 Inhibitors in NSTE-ACS: Selective vs. Routine?
  11. EPC Capture Stent : A Promising Solution Amongst the DAPT Controversy?
  12. The DAPT Debate - 2016
  13. Upcoming Trend in ACS Patient Management
  14. The DAPT Duration Debate - Practical Synthesis and Clinical Recommendations
  15. Vulnerable Plaque Is a Systemic Disease: Insights from BioImage
  16. Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back?
  17. Optimal DAPT Duration for Current and Future DES and BVS
  18. Will Long Term Dual Antiplatelet Therapy Improve LT Outcome?
  19. Does True Vessel Healing Matter?
  20. Interventional Pharmacology - Year in Review 
  21. No Benefits, Possible Harms - The ACCOAST Trial
  22. The Next Era: COMBO Dual Therapy Stent
  23. [Bivalirudin: Is It Standard of Care in the Cath Lab?] No, Heparin with Provisional GPI Is Still a Viable Option.
  24. Surveying the Landscape of New Anti-platelet Agents: A Practical User¡¯s Guide
  25. Update on Left Main/Multivessel PCI: Lessons from SYNTAX, a View to EXCEL
  26. Impact of Bleeding and Tailored or Personalized Antiplatlet Therapy to Reduce Bleeding in ACS or PCI Patients: From Clopidogrel to Prasugrel and Ticagrelor
  27. Bleeding & Mortality: Beyond the Horizon
  28. The NEW Anti-platelet Agents and Platelet Reactivity Testing: Recommendations for Prasugrel and Ticagrelor and Lessons from GRAVATAS
  29. Behind Closed Doors: Functions of a Data Safety Monitoring Board
  30. Types of Clinical Trials in Cardiology: The Rationale for Trial Design
  31. PCI in Chronic Kidney Disease (RECOVER, CARE, LOCM-Related Studies, and Meta-Analysis)
  32. Parenteral Anticoagulants Use in ACS (HORIZONS-AMI, and SEPIA-ACS Trial)
  33. The Role of New Anti-platelet Agents: Will Prasugrel and Ticagrelor Change the DES Landscape?
  34. Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib
  35. New Paradigms in Treatment of ACS/AMI
  36. Quality Control of Clinical Trials: Blinding, Clinical Event Committees, Core Labs, and Data Standards
  37. ACS/AMI: What¡¯s Hot, What¡¯s Not!
  38. Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS
  39. The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials
  40. TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI
  41. In-Stent Restenosis
  42. HORIZONS AMI: Bivalirudin vs. Unfractionated Heparin plus GPIIb/IIIa Inhibitors in STEMI
  43. The Interventional Trials of the Year: 2007-2008 (TCT, AHA, and ACC)
  44. The CoStar Clinical Data
  45. ACUITY: One Year Outcome of ACUITY Trial
  46. Renal Failure and Contrast Nephropathy: An Overview and Considerations in the PCI Patient
  47. The Interventional Trials of the Year: 2006-2007 (TCT, AHA, and ACC)
  48. Complications Related to the Use of Radiocontrast Agents
  49. A Prospective "All Comers" CYPHER Nonrandomized Registry in Complex Patients From MATRIX
  50. Revised Protocol of COMBAT(Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease)
  51. Radiocontrast Nephropathy: Still the Achilles' Heel of Interventional Cardiology
  52. Countdown to COMBAT